EBVaGC patients have a unique immune microenvironment, with more immune-active cells infiltrating the tumor microenvironment, such as CD8+ cytotoxic T cells and mature dendritic cells, forming an immune-activated phenotype (22, 23). This evidence concerns the gene CD8A and neoplasm.